Predict your next investment

Venture Capital

See what CB Insights has to offer

Investments

41

Portfolio Exits

17

About JAFCO Life Science Investment

JAFCO Life Science Investment, part of Tokyo-based publicly-traded venture capital firm JAFCO, aims to invest in U.S.-based later-stage biopharmaceutical and medical device companies and create value for portfolio companies by facilitating partnerships with Japanese companies. JAFCO has extensive networks with pharmaceutical and medical device companies in Japan and holds a JAFCO Biotechnology Conference in November of every year in Tokyo.

JAFCO Life Science Investment Headquarter Location

Tokyo,

Japan

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest JAFCO Life Science Investment News

Tracon Raises $14M to Advance Cancer Drug

Apr 20, 2011

XconomySan Diego —  San Diego’s Tracon Pharmaceuticals says today it has raised $14 million of a planned $22 million round of venture capital needed to advance development of TRC105, a promising therapeutic that inhibits the growth of new blood vessels that supply tumors. The National Cancer Institute also is supporting the company’s research and development, which includes ongoing trials in prostate, bladder, and liver cancer. JAFCO, the Tokyo-based, publicly traded venture capital group, and Nextech Invest, a specialized oncology fund based in Zurich, Switzerland, led the investment round. They were joined by New York-based Arcus Ventures and the Tokyo-based venture firm BHP. Existing investor Brookline Investments of Birmingham, AL, also participated. In a statement from the company , Tracon CEO Charles Theuer says the funding will enable the company to build on promising early stage research and complete multiple mid-stage trials of the antibody TRC105. Tracon says it is testing the antibody on a new tumor vascular target known as CD-105, as both a monotherapy and in combination with existing vascular endothelial growth factor (VEGF) inhibitors as well as chemotherapy. JAFCO’s Kenji Harada and Hironori Hozoji (a San Diego-based investment officer with JAFCO Life Science Investment) are joining Tracon’s board, along with Nextech managing partner Myoung-Ok Kwon. Tracon says two prominent oncologists, Harvard University’s William G. Kaelin and Charles L. Sawyers of the Memorial Sloan-Kettering Cancer Center also were named to the company’s scientific advisory board.

JAFCO Life Science Investment Investments

41 Investments

JAFCO Life Science Investment has made 41 investments. Their latest investment was in Complexa as part of their Series C - II on April 4, 2019.

CBI Logo

JAFCO Life Science Investment Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/16/2019

Series C - II

Complexa

$11M

No

2

9/28/2017

Series B

Magenta Medical

$15M

Yes

5

7/26/2017

Series C

Complexa

$62M

No

4

6/4/2014

Series B

Subscribe to see more

$99M

Subscribe to see more

10

12/2/2013

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/16/2019

9/28/2017

7/26/2017

6/4/2014

12/2/2013

Round

Series C - II

Series B

Series C

Series B

Series B

Company

Complexa

Magenta Medical

Complexa

Subscribe to see more

Subscribe to see more

Amount

$11M

$15M

$62M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

5

4

10

10

JAFCO Life Science Investment Portfolio Exits

17 Portfolio Exits

JAFCO Life Science Investment has 17 portfolio exits. Their latest portfolio exit was Sesen Bio on February 06, 2014.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/6/2014

IPO

$99M

Public

2

10/11/2012

IPO

$99M

Public

1

10/11/2012

IPO

$99M

Public

10/8/2012

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

11/23/2011

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

Date

2/6/2014

10/11/2012

10/11/2012

10/8/2012

11/23/2011

Exit

IPO

IPO

IPO

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Public

Subscribe to see more

Subscribe to see more

Sources

2

1

10

0

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.